Over-the-counter medicine
Butenafine Brand names: Lotrimin; first approved as Mentax
Butenafine (Lotrimin) is an over-the-counter medicine with an FDA approval on record since 1996. FDA's NDC Directory lists it from 13 generic labelers, and pharmacies paid $0.419 per gram (Butenafine HCl 1% cream) in the October 7, 2026 NADAC survey.
- Generic listed
- Over the counter
Check it at the source: the butenafine FDA label on DailyMed (effective December 5, 2025, Bayer Healthcare LLC.); the NDA 20524 record on Drugs@FDA; every butenafine label on DailyMed.
Highlights of the record
FDA label of December 5, 2025; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usagecures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition
Forms and strengths
- 1 g/100g
- 10 mg/g
Cream.
On the market
- Earliest approval on file
- October 18, 1996 Mentax, Pharmobedient; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first November 16, 2017; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 14 of which 13 under generic applications, 1 under brand applications, repackagers included
Supply and safety
- Pharmacy cost (NADAC)
- $0.419 per gram Butenafine HCl 1% cream
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 586 through July 30, 2026
What is butenafine used for?
From the label: indications and usagecures most jock itch relieves itching, burning, cracking, and scaling which accompany this condition
FDA pharmacologic class: Benzylamine Antifungal.
Source: FDA drug label (Lotrimin Ultra Jock Itch), Bayer Healthcare LLC., effective December 5, 2025 (SPL set 9dfa08fb-0913-4326-b1eb-1425df6a2c82), via openFDA; the full label on DailyMed
Is there a generic for butenafine (Lotrimin)?
The FDA approved the first generic butenafine on November 16, 2017. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
FDA's NDC Directory lists butenafine from 13 labelers under a generic (ANDA) application and from 1 brand labeler. A listing means the company has registered the product for sale; it does not show that every pharmacy stocks it.
- 1996 earliest approval on file
- 2017 first generic approved
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for butenafine (Lotrimin)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $0.419 per gram (Butenafine HCl 1% cream), up 28% from $0.328 on October 8, 2025. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Butenafine HCl 1% cream (generic)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Butenafine HCl 1% cream | Generic | $0.419 per gram | n/a | +28% |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What do FAERS reports show for butenafine?
The FDA Adverse Event Reporting System holds 586 reports that list butenafine among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 7 are coded as a death and 24 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Butenafine side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other